Banana NewsFresh news, peeled daily
WorldU.S.PoliticsBusinessMarketsCryptoTechnologyAIScienceHealthSportsEntertainmentClimate & EnvironmentRochester
1,780,923 archived · 53,814 today
World
LA NYC São Paulo London Paris Lagos Dubai Delhi Singapore Tokyo Sydney
Pulse
English · Not set Change ▾

Live scores ticker: On · Turn off

Markets ticker: On · Turn off

Saved in a cookie on this device (and in your account when you are logged in). We never store your IP address.

Entities › name

SEL

8 headlines · 5 outlets · 2026-10-12 → 2026-11-05 · Wikipedia ↗ · 🔒 Follow

Latest coverage

PR Newswire: Health · ☆
  • Press releases
  • Country: United States

Die Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten Patienten mit rezidiviertem/refraktärem aggressivem B-Zell-Non-Hodgkin-Lymphom bekannt

Erste klinische Daten zur Dapolsertib-Monotherapie: Erste Ergebnisse der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703), einem First-in-Class-Inhibitor der PIM- und FLT3-Kinase zur oralen Einnahme, bei Patienten mit rezidiviertem/refraktärem (r/r) aggressivem...

Health Details Archived copy ↗
PR Newswire: Health · ☆
  • Press releases
  • Country: United States

Menarini Group et Ryvu Therapeutics annoncent les premières données cliniques de l'étude de phase II JASPIS-01 sur le dapolsertib (MEN1703, SEL24)

Menarini Group et Ryvu Therapeutics annoncent les premières données cliniques de l'étude de phase II JASPIS-01 sur le dapolsertib (MEN1703, SEL24) chez des patients atteints d'un lymphome non hodgkinien à cellules B agressif, récidivant ou réfractaire, fortement prétraités, lors du...

Health Details Archived copy ↗
PR Newswire: Health · ☆
  • Press releases
  • Country: United States

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted...

EntertainmentHealthSports Details Archived copy ↗
PR Newswire: Technology · ☆
  • Press releases
  • Country: United States

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted...

EntertainmentHealthSportsTechnology Details Archived copy ↗
Newswire.ca · ☆
  • Press releases
  • Country: Canada

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted...

BusinessEntertainmentHealthSports Details Archived copy ↗

Explore

News

📈Trending💹Markets🏷️Topics🗞️Sources👤People & places⚖️Perspectives🌍Map🗓️Timeline

Daily

📋All daily lists

Banana Watch & guides

🍌Banana Originals🍌Banana Watch📺Live TV🌐Government live🏛️White House🗓️TV guide🔟Top 10 this week📱Shorts🏟️Official scores☀️Today's brief

Elections 2026

🗳️Elections✅How to vote📊Polls explained⏱️Election night

Watch & listen

🎬Videos🍿Shows & Movies🎭Entertainment🎵Music🎙️Podcasts📻Live Radio & Scanners🏎️Games

Sports

🔴Sports Live📺Sports Watch📊Odds tracker

Local & weather

📍Near you🌦️Weather & radar🏳️Countries

Understand & explore

🧩Same story🔁What changed🏁Who's first🌐Web trends❓Why it's trending🔗Compare an article📜On this day⏳Time Machine🐇Rabbit hole📰Front page📚Free books🧠Daily quiz🔮Forecasts (play money)

Join

🔑Log in🍌Sign up 📲Notifications🍌Calm mode📦Offline pack

Banana News

0 paying members keep Banana News going

⭐Pricing🍌Banana Coin✍️Creatorsℹ️About

Banana News Single Banana

Upgrade to unlock this

See plans Log in

Free accounts get fresh bananas every day. Cancel anytime · pay by card or USDC on Base · compare all plans

↑↓ move · ↵ go · ? shortcuts

Keyboard shortcuts

Move

j / k next / previous story

o or ↵ open original

d story details

b bookmark

Go

g h home · g f front page

g t timeline · g y time machine

g b briefing · g p perspectives

g m map · g o on this day

g r rabbit hole · g w wrapped

Everywhere

/ search

Ctrl/⌘ K command palette

t cycle theme

? this help · Esc close

Shortcuts never fire while you are typing, and are off when you hold Ctrl, Alt or ⌘.

Ask Ara

Ara answers only from Banana News. Your voice stays in your browser; nothing is saved.

What each plan gets here

Every plan (Single Banana, Bunch, Crate, Banana Tree): Everything - voice, all 15 languages (Ara's own voice where it's ready, text otherwise - never a robot voice), know-how. Ara is free for everyone.

Compare plans